Allogene Therapeutics (ALLO) Competitors $1.20 -0.01 (-0.83%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 10/24/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. LENZ, COLL, XNCR, MNMD, TNGX, BCAX, SPRY, SEPN, ANAB, and PHARShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include LENZ Therapeutics (LENZ), Collegium Pharmaceutical (COLL), Xencor (XNCR), Mind Medicine (MindMed) (MNMD), Tango Therapeutics (TNGX), Bicara Therapeutics (BCAX), ARS Pharmaceuticals (SPRY), Septerna (SEPN), AnaptysBio (ANAB), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Its Competitors LENZ Therapeutics Collegium Pharmaceutical Xencor Mind Medicine (MindMed) Tango Therapeutics Bicara Therapeutics ARS Pharmaceuticals Septerna AnaptysBio Pharming Group Allogene Therapeutics (NASDAQ:ALLO) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Which has stronger earnings and valuation, ALLO or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$20K13,312.80-$257.59M-$1.11-1.08LENZ TherapeuticsN/AN/A-$49.77M-$1.90-16.83 Is ALLO or LENZ more profitable? LENZ Therapeutics' return on equity of -25.63% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -55.99% -42.75% LENZ Therapeutics N/A -25.63%-24.43% Do institutionals and insiders believe in ALLO or LENZ? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ALLO or LENZ? Allogene Therapeutics currently has a consensus target price of $8.44, indicating a potential upside of 603.70%. LENZ Therapeutics has a consensus target price of $54.80, indicating a potential upside of 71.41%. Given Allogene Therapeutics' higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 2 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.54LENZ Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media refer more to ALLO or LENZ? In the previous week, LENZ Therapeutics had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 10 mentions for LENZ Therapeutics and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.90 beat LENZ Therapeutics' score of 0.70 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ALLO or LENZ? Allogene Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. SummaryAllogene Therapeutics beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$266.26M$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio-1.0828.5131.6030.98Price / Sales13,312.80497.40595.06133.64Price / CashN/A46.9537.2561.86Price / Book0.6010.4012.056.61Net Income-$257.59M-$52.83M$3.34B$277.10M7 Day Performance-2.44%2.10%1.94%2.57%1 Month Performance-4.00%10.17%6.88%3.20%1 Year Performance-50.82%16.57%56.06%33.22% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics3.443 of 5 stars$1.20-0.8%$8.44+603.7%-50.8%$266.26M$20K-1.08310News CoverageAnalyst ForecastLENZLENZ Therapeutics2.3058 of 5 stars$36.31-5.1%$54.80+50.9%+18.3%$1.09BN/A-19.11110Positive NewsAnalyst UpgradeGap UpCOLLCollegium Pharmaceutical3.6736 of 5 stars$34.85+2.7%$42.33+21.5%+1.7%$1.07B$631.45M33.51210News CoverageAnalyst DowngradeXNCRXencor3.8007 of 5 stars$15.07+2.0%$24.22+60.7%-37.6%$1.05B$110.49M-6.28280News CoverageMNMDMind Medicine (MindMed)3.1312 of 5 stars$13.16-3.6%$27.83+111.5%+104.6%$1.04BN/A-8.6040Analyst ForecastTNGXTango Therapeutics2.0744 of 5 stars$9.15+1.3%$10.50+14.8%+26.3%$1.00B$42.07M-6.8890Trending NewsAnalyst ForecastAnalyst RevisionGap UpBCAXBicara Therapeutics2.6547 of 5 stars$16.26-10.9%$31.86+95.9%-23.8%$996.68MN/A-5.1332High Trading VolumeSPRYARS Pharmaceuticals3.1472 of 5 stars$10.01-0.4%$33.80+237.7%-38.3%$993.21M$89.15M-20.4390News CoverageAnalyst DowngradeSEPNSepterna1.75 of 5 stars$22.44+1.7%$26.75+19.2%N/A$983.55M$1.08M-2.22N/AAnalyst ForecastANABAnaptysBio2.9445 of 5 stars$35.28+1.9%$54.78+55.3%+9.5%$969.53M$91.28M-7.87100Analyst ForecastPHARPharming Group2.6492 of 5 stars$14.07+0.5%$30.00+113.3%+56.3%$959.21M$297.20M-108.19280Analyst UpgradeGap Down Related Companies and Tools Related Companies LENZ Competitors COLL Competitors XNCR Competitors MNMD Competitors TNGX Competitors BCAX Competitors SPRY Competitors SEPN Competitors ANAB Competitors PHAR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
